Allergan's LUMIGAN Receives Positive Opinion for Approval in Europe.Business Editors & Health/Medical Writers IRVINE, Calif.--(BW HealthWire)--Nov. 19, 2001 Allergan, Inc. (NYSE NYSE See: New York Stock Exchange :AGN AGN Again (Amateur Radio) AGN Active Galactic Nucleus AGN Acute Glomerulonephritis AGN Accountants Global Network AGN Air Gabon (ICAO code) ) today announced that the Committee for Proprietary Medicinal Products (CPMP CPMP Committee for Proprietary Medicinal Products CPMP Core-Plus Mathematics Project CPMP Crew Procedures Management Plan (NASA) CPMP Canadian Project Management Professional CPMP Corporate Planning and Management Practices ) recommended LUMIGAN(R) (bimatoprost ophthalmic solution ophthalmic solution n. A sterile solution that is free from foreign particles and is compounded and dispensed for eyedrops. , 0.03%), the Company's new glaucoma therapy, be approved by the European Commission. The CPMP opinion serves as the basis for European Commission approval, which is typically issued in approximately three months. In addition to the U.S. Food and Drug Administration approval in March 2001, LUMIGAN(R) has also received approval in six Latin American countries. As of September 28, 2001, year-to-date sales for LUMIGAN(R) were $20.3 million. About Allergan, Inc. Allergan, Inc., with headquarters in Irvine, California, is a technology-driven, global healthcare company, providing eye care and specialty pharmaceutical products worldwide. Allergan develops and commericalizes products in the eye care pharmaceutical, ophthalmic surgical device, over-the-counter contact lens contact lens, thin plastic lens worn between the eye and eyelid that may be used instead of eyeglasses. Actors, models, and others wear them for appearance, and athletes use them for safety and convenience. care, movement disorder and dermatological markets that deliver value to our customers, satisfy unmet medical needs and improve patients' lives. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion